CONTE, Pierfranco

CONTE, Pierfranco  

Mostra records
Risultati 1 - 20 di 381 (tempo di esecuzione: 0.03 secondi).
Titolo Data di pubblicazione Autore(i) File
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 1-gen-2017 Conte, P; Bisagni, G; Frassoldati, A; Brandes, A; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Musolino, A; Garrone, O; Donadio, M; Cavazzini, G; Turletti, A; Zamagni, C; Danese, S; Ferro, A; Piacentini, F; Balduzzi, S; D'Amico, R; Guarneri, V
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 1-gen-2010 Barbieri, E.; Bettelli, S.; Piacentini, F.; Ficarra, G.; Conte, Pf.; Guarneri, V.
4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study. 1-gen-1987 M., Bruzzone; S., Chiara; A., Falcone; G., Graziani; Conte, Pierfranco; R., Rosso
41. HER2+ EARLY BREAST CANCER: DO WE HAVE ALL THE NECESSARY ANSWERS? 1-gen-2012 Conte, P.; Verrusio, Manuela; Piacentini, F.
5-fluorouracil administered as a 48-hour semi-intermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients 1-gen-2004 Allegrini, G; Falcone, A; DI MARSICO, R; Lencioni, M; Masi, G; Galli, C; Cupini, S; Pfanner, E; Marcucci, L; Conte, Pierfranco
5-Fluoruracil administered as a 48-hours chronomodulated infusion in combination with Leucovorin and Cisplatin: a randomized phase II study in metastatic colorectal cancer. 1-gen-2001 A., Falcone; G., Allegrini; G. L., Masi; M., Lencioni; E., Pfanner; I., Brunetti; R., Danesi; G., Bocci; M., Del Tacca; Conte, Pierfranco
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 1-gen-2018 Conte, P; Frassoldati, A; Bisagni, G; Brandes, Aa; Donadio, M; Garrone, O; Piacentini, F; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Molino, A; Musolino, A; Ferro, A; Maltoni, R; Danese, S; Zamagni, C; Rimanti, A; Cagossi, K; Russo, A; Pronzato, P; Giovanardi, F; Moretti, G; Lombardo, L; Schirone, A; Beano, A; Amaducci, L; Bajardi, Ea; Vicini, R; Balduzzi, Sara; D'Amico, R; Guarneri, Valentina
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 1-gen-2010 Guarneri, Valentina; Frassoldati, A; Gebbia, V; Bisagni, G; Cavanna, L; Donadio, M; Lelli, G; Musolino, A; Colucci, G; Banna, Gl; Degli Esposti, R; Ferro, A; Grasso, F; Zamagni, C; Amadori, D; Aieta, M; Molino, A; Garrone, O; Aitini, E; Fornari, G; Cascinu, Stefano; Rossi, G; D'Amico, Roberto; Conte, Pierfranco
A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. 1-gen-1997 A., Michelotti; B., Salvadori; S., Donati; A., Tognoni; C., Tibaldi; Conte, Pierfranco
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region. 1-gen-1993 S., Spagnesi; F., Ducci; M., Laddaga; A., Falcone; Conte, Pierfranco; A., Pandolfi; C. G., Stampino
A phase II study of mitoxantrone in advanced breast cancer. 1-gen-1986 P., Pronzato; A., Ardizzoni; Conte, Pierfranco; M., Gulisano; R., Lionetto; L., Repetto; V., Scornavacche; M. R., Sertoli; R., Rosso
A phase II study with danazol in metastatic breast cancer. 1-gen-1987 P., Pronzato; D., Amoroso; A., Ardizzoni; G., Bertelli; Conte, Pierfranco; A., Michelotti; R., Rosso
A pilot study with cisplatin, ifosfamide and weekly administration of vinorelbine as an outpatient combination chemotherapy for advanced non small cell lung cancer. 1-gen-1996 C., Tibaldi; E., Baldini; S., Ricci; Conte, Pierfranco
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 1-gen-2008 Guarneri, Valentina; Piacentini, Federico; A., Frassoldati; G., Ficarra; D'Amico, Roberto; Giovannelli, Simona; Conte, Pierfranco
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. 1-gen-2009 Guarneri, Valentina; Piacentini, Federico; Ficarra, G; Frassoldati, A; D'Amico, Roberto; Giovannelli, Simona; Maiorana, Antonino; Jovic, Gordana; Conte, Pierfranco
A Randomized Study Comparing Two Different Schedules of Administration of Cisplatin in Combination With Gemcitabine in Advanced non Small Cell Lung Carcinoma. 1-gen-2000 T., Ricci; A., Antonuzzo; L., Galli; C., Tibaldi; M., Bertuccelli; A., Lopes Pegna; S., Petruzzelli; V., Bonifazzi; C., Orlandini; Conte, Pierfranco
A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. 1-gen-1986 Conte, Pierfranco; M., Bruzzone; S., Chiara; M. R., Sertoli; M. G., Daga; A., Rubagotti; A., Conio; M., Ruvolo; R., Rosso; L., Santi
A randomized trial of chemotherapy with or without estrogenic recruitment in locally advanced breast cancer. North-West Oncology Group (GONO) Study, Italy. 1-gen-1997 E., Baldini; G., Gardin; P., Giannessi; F., Brema; A., Camorriano; F., Carnino; C., Naso; G., Pastorino; P., Pronzato; R., Rosso; A., Rubagotti; G., Torretta; Conte, Pierfranco
Abdominopelvic radiotherapy following surgery and chemotherapy in advanced ovarian cancer. 1-gen-1991 S., Chiara; M., Orsatti; P., Franzone; D., Scarpati; M., Bruzzone; L., Repetto; V., Vitale; Conte, Pierfranco; R., Rosso
Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas. 1-gen-1996 A., Michelotti; A., Romanini; P., Giannessi; C., Bengala; Conte, Pierfranco